R
RS Research
Clinically-validated biotech company for targeted therapies with disruptive safety and efficacy
About RS Research
RS Research is a clinical-stage biotech company advancing Sagitta® smart nanomedicines and clinically validated polymer-drug conjugates for targeted chemotherapy, disrupting the efficacy-toxicity trade-off. Phase 1 validation, Phase 2 readiness, European Medicines Agency SME status and in-house GMP signal near-term milestones and a scarce, high-upside opportunity, with a rich pipeline and multiple candidates advancing.Its lead asset, RS-0139, has completed Phase 1, demonstrating markedly improved hematologic safety versus conventional chemotherapy as well as promising efficacy signals. The company is currently consolidating the dataset for a near-term public disclosure.
EIC European Prize for Women Innovators laurate Prof. Rana Sanyal is the Co-Founder and CSO of RS Research. She has an extensive background in medicinal chemistry, with a PhD from Boston University and experience at Amgen. She has been a professor at Boğaziçi University since 2004, focusing on targeted drug delivery systems, and is an inventor on over 50 patents.
Co-founder and COO, Sena Nomak, PhD, is a serial entrepreneur in defense and biotech industris.
The company has secured significant funding, including a seed round of €2 million in 2017 from ACT Venture Partners (VC). This was followed by a Series A round of $12 million in 2021, led by GEN (Pharma) with participation from Eczacıbaşı Momentum (Pharma CVC) and İstanbul Portföy )VC).
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Istanbul, Türkiye
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 89.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Drug Delivery Systems, slush24, DT and LS
- Technology
- Deep Tech, Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $12M | $48M | Gen Ilac · OneLife Ventures · Eczacıbasi Momentum · Gen Pharmaceuticals | ↗ |
| CONVERTIBLEEquity / VC | Jan 2018 | $990K | — | ACT Venture Partners | — |
Growth signals
Latest recorded traffic for RS Research is 560 monthly website visits, down 6.7% over the last three months. RS Research's team grew 61.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
ACT Venture Partners- GPGen Pharmaceuticals
Gen Ilac- OVOneLife Ventures
Eczacıbasi Momentum
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RS Research on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RS Research’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.